Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. (Q43244972)

17 November 2017

Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. (English)

1 reference

17 November 2017

1 reference

1

1 reference

17 November 2017

2

1 reference

17 November 2017

D R Brocks

3

1 reference

PubMed ID

19903013

17 November 2017

A Lavasanifar

series ordinal

4

1 reference

PubMed ID

19903013

17 November 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

17 November 2017

1 reference

17 November 2017

40

1 reference

17 November 2017

55-61

1 reference

17 November 2017

1

1 reference

Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution

17 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Valspodar: current status and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Role of cytochromes P450 in drug metabolism and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903331056

10.3109/00498250903331056

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference

PubMed ID

19903013